Get the Stockscreener App
1.52
1.94%
-0.03
After Hours:
1.52
Acrivon Therapeutics Inc stock is traded at $1.52, with a volume of 875.94K.
It is down -1.94% in the last 24 hours and up +21.60% over the past month.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
See More
Previous Close:
$1.55
Open:
$1.55
24h Volume:
875.94K
Relative Volume:
0.76
Market Cap:
$47.81M
Revenue:
-
Net Income/Loss:
$-69.00M
P/E Ratio:
-0.5468
EPS:
-2.78
Net Cash Flow:
$-55.26M
1W Performance:
+14.29%
1M Performance:
+21.60%
6M Performance:
-71.48%
1Y Performance:
-83.55%
1-Day Range:
$1.46
$1.57
1-Week Range:
$1.35
$2.67
52-Week Range:
$1.05
$10.00
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Name
Acrivon Therapeutics Inc
Sector
Industry
Phone
617-207-8979
Address
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.52 | 51.27M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Resumed | Piper Sandler | Overweight |
| Jan-31-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-29-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| Dec-15-23 | Resumed | Jefferies | Buy |
| Oct-05-23 | Initiated | Maxim Group | Buy |
| Jun-02-23 | Initiated | Oppenheimer | Outperform |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Apr-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Apr-20-23 | Initiated | H.C. Wainwright | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Dec-12-22 | Initiated | Jefferies | Buy |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
View All
Acrivon Therapeutics Inc Stock (ACRV) Latest News
Automated trading signals detected on Acrivon Therapeutics Inc.Entry Point & AI Forecasted Entry/Exit Points - Newser
Is Acrivon Therapeutics Inc. showing signs of accumulation2025 Short Interest & Verified Technical Signals - Newser
Using RSI to spot recovery in Acrivon Therapeutics Inc.July 2025 Outlook & Short-Term High Return Ideas - Newser
Chart based analysis of Acrivon Therapeutics Inc. trendsWeekly Trend Report & Community Trade Idea Sharing Platform - Newser
Is Acrivon Therapeutics Inc. meeting your algorithmic filter criteriaQuarterly Trade Review & Breakout Confirmation Trade Signals - Newser
How to use a screener to detect Acrivon Therapeutics Inc. breakoutsQuarterly Profit Review & Low Risk High Win Rate Stock Picks - Newser
Using Ichimoku Cloud for Acrivon Therapeutics Inc. technicals2025 Historical Comparison & Momentum Based Trading Signals - Newser
Acrivon Therapeutics Inc. stock prediction for this weekSwing Trade & Safe Investment Capital Preservation Plans - Newser
Acrivon Therapeutics Inc. stock trend forecastMarket Risk Analysis & Low Volatility Stock Suggestions - Newser
What indicators show strength in Acrivon Therapeutics Inc.July 2025 Patterns & Fast Entry and Exit Trade Plans - Newser
Technical analysis overview for Acrivon Therapeutics Inc. stockJuly 2025 Movers & Reliable Volume Spike Alerts - Newser
Will Acrivon Therapeutics Inc. benefit from macro trendsTrade Analysis Report & Verified Swing Trading Watchlists - Newser
Detecting price anomalies in Acrivon Therapeutics Inc. with AI2025 Price Targets & Safe Entry Momentum Stock Tips - Newser
How moving averages guide Acrivon Therapeutics Inc. tradingEarnings Overview Report & Fast Momentum Stock Entry Tips - Newser
Visual trend scoring systems applied to Acrivon Therapeutics Inc.2025 Performance Recap & Verified Trade Idea Suggestions - Newser
Tick level data insight on Acrivon Therapeutics Inc. volatility2025 Volatility Report & Proven Capital Preservation Tips - Newser
Long term hold vs stop loss in Acrivon Therapeutics Inc.Gold Moves & Breakout Confirmation Trade Signals - Newser
Is this a good reentry point in Acrivon Therapeutics Inc.2025 Key Lessons & Weekly Top Stock Performers List - Newser
Forecasting Acrivon Therapeutics Inc. price range with options dataJuly 2025 Analyst Calls & Low Risk Investment Opportunities - Newser
will acrivon therapeutics inc. benefit from macro trends2025 Retail Activity & Reliable Trade Execution Plans - Newser
Is Acrivon Therapeutics Inc. stock a good hedge against inflationMarket Rally & Smart Investment Allocation Tips - Newser
How hedge fund analytics apply to Acrivon Therapeutics Inc. stockMarket Growth Review & Capital Protection Trade Alerts - Newser
Acrivon Therapeutics Inc. stock chart pattern explainedJuly 2025 PostEarnings & High Return Trade Opportunity Guides - Newser
Has Acrivon Therapeutics Inc. found a price floorGlobal Markets & Real-Time Buy Zone Alerts - Newser
Full technical analysis of Acrivon Therapeutics Inc. stockWall Street Watch & Free Technical Confirmation Trade Alerts - Newser
Analyzing net buyer seller activity in Acrivon Therapeutics Inc.Weekly Gains Summary & Risk Adjusted Swing Trade Ideas - Newser
Understanding Acrivon Therapeutics Inc.’s price movement2025 Breakouts & Breakdowns & Consistent Income Trade Ideas - Newser
Is Acrivon Therapeutics Inc. stock entering bullish territoryRecession Risk & AI Forecast Swing Trade Picks - Newser
Is Acrivon Therapeutics Inc. trending in predictive chart modelsRate Cut & Real-Time Volume Trigger Notifications - Newser
Published on: 2025-09-09 18:21:35 - Newser
Acrivon Therapeutics Highlights Synergy in Updated Presentation - MSN
How to build a dashboard for Acrivon Therapeutics Inc. stockMarket Growth Summary & Stepwise Trade Execution Plans - Newser
Can volume confirm reversal in Acrivon Therapeutics Inc.July 2025 Pullbacks & Weekly Top Gainers Alerts - Newser
Will Acrivon Therapeutics Inc. benefit from green energy policiesEarnings Performance Report & High Conviction Investment Ideas - Lancaster City Council
Multi factor analysis applied to Acrivon Therapeutics Inc.Earnings Beat & Stock Portfolio Risk Control - Newser
Should you wait for a breakout in Acrivon Therapeutics Inc.2025 Breakouts & Breakdowns & Technical Pattern Based Signals - Newser
Acrivon Therapeutics Inc Stock (ACRV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):